Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

L9761

Sigma-Aldrich

[D-Trp6]-LH-RH

≥97% (HPLC), powder

Sinónimos:

[D-Trp6]-Luteinizing hormone releasing hormone

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C64H82N18O13
Número de CAS:
57773-63-4
Peso molecular:
1311.45
Número MDL:
MFCD00167541
Código UNSPSC:
12352209
ID de la sustancia en PubChem:
329817674
NACRES:
NA.32

Ensayo

≥97% (HPLC)

Formulario

powder

Nº de acceso UniProt

P01148
P30968

temp. de almacenamiento

−20°C

cadena SMILES

CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H](Cc4c[nH]c5ccccc45)NC(=O)[C@H](Cc6c[nH]cn6)NC(=O)[C@@H]7CCC(=O)N7)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N8CCC[C@H]8C(=O)NCC(N)=O

InChI

1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1

Clave InChI

VXKHXGOKWPXYNA-PGBVPBMZSA-N

Información sobre el gen

human ... GNRH1(2796) , GNRHR(2798)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Amino Acid Sequence

Glp-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2

Aplicación

[D-Trp6]-LH-RH (luteinizing hormone releasing hormone) has been used to study whether the (M. – X) region in electron capture dissociation provides information on amino acid composition of polypeptides. It is also used to study the effect of LH-RH on the production of progesterone (P), estradiol (E2) or human chorionic gonadotropin (hCG) by JEG-3 choriocarcinoma cells.

Acciones bioquímicas o fisiológicas

Potent LH-RH agonist with enhanced biological activity due to its slower rate of degradation. Like [D-Lys6]-LH-RH, the D-Trp6 analog has been shown to be effective against cancers expressing the LH-RH receptor. However, unlike the D-Lys6 analog, it is generally used in the unconjugated form.

Envase

Bottomless glass bottle. Contents are inside inserted fused cone.

Pictogramas

Health hazard
GHS08

Palabra de señalización

Danger

Frases de peligro

H360

Consejos de prudencia

P201 - P308 + P313

Clasificaciones de peligro

Repr. 1B

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Equipo de protección personal

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
BCCH1269
BCCB4898
BCBX4005
BCBT0543
BCBQ4733V

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Sandra Goericke-Pesch et al.
Theriogenology, 79(4), 640-646 (2012-12-26)
Although slow release GnRH-agonist implants have been shown to effectively suppress the estrous cycle in queens, there are still several remaining questions about their use: if the probability and frequency of estrus induction because of initial stimulation is dependent on
T Wolf et al.
Reproduction in domestic animals = Zuchthygiene, 47 Suppl 6, 387-388 (2013-01-04)
Four German Shorthair Pointer bitches each produced from two to five (total of 14) purebred litters in response to natural matings to either natural oestrus (n = 8) or oestrus induced by Ovuplant(®), a sustained-release implant containing 2.1 mg deslorelin
Colette Meyer et al.
Endocrine-related cancer, 20(1), 123-136 (2012-12-04)
GNRH significantly inhibits proliferation of a proportion of cancer cell lines by activating GNRH receptor (GNRHR)-G protein signaling. Therefore, manipulation of GNRHR signaling may have an under-utilized role in treating certain breast and ovarian cancers. However, the precise signaling pathways
T Kádár et al.
Physiology & behavior, 51(3), 601-605 (1992-03-01)
The neuropharmacological actions of the agonist analog D-Trp-6-LH-RH were investigated in several tests after intracerebroventricular (ICV) administrations to male rats. The doses applied were 10, 100 and 1000 ng/animal. In the open field the 1000 ng ICV dose of the
S Romagnoli et al.
Reproduction in domestic animals = Zuchthygiene, 47 Suppl 6, 389-392 (2013-01-04)
The purpose of this study was to define (i) the interval between treatment and sterility, and (ii) semen quality in male dogs administered a 4.7-mg deslorelin implant. Six healthy, adult dogs of various breeds and body weights were implanted with
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico